Clinical trials: B Cell
Follicular Lymphoma, Diffuse Large Cell Lymphoma
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies
This is an open-label, multicenter, phase II study to evaluate the safety and efficacy of single-agent AT-101 in patients with relapsed or refractory B-cell malignancies.
- Conditions
- Follicular Lymphoma, Diffuse Large Cell Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT00275431
- Testing
- AT-101
- Where
- 11 sites in United States
- Volunteers
- 50 people
- Sponsor
- Ascenta Therapeutics
Lymphoma, B-Cell, Marginal Zone
Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma
The purpose of this study is to assess the efficacy and safety of Ibrutinib in predominantly Asian patients with relapsed or refractory marginal zone lymphoma.
- Trial name
- NCT03093831
- Testing
- Ibrutinib
- Where
- 2 sites in Singapore
- Volunteers
- 5 people
- Sponsor
- National Cancer Centre, Singapore
B-cell Non Hodgkin Lymphoma
Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)
This is a prospective, multi-center, open phase I/II trial to evaluate feasibility, dosage, safety and toxicity as well as efficacy of ex vivo expanded autologous T cells genetically modified to express anti-CD20 and CD19…
- Trial name
- NCT03870945
- Testing
- MB-CART2019.1 Dose level 1, MB-CART2019.1 Dose level 2
- Where
- 3 sites in Germany
- Volunteers
- 12 people
- Sponsor
- Miltenyi Biomedicine GmbH
Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia
Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies
Background: About 23,000 people die from B-cell cancers in the US each year. These cancers, often called leukemia or lymphoma, affect a type of white blood cell called B cells.
- Conditions
- Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell
- Trial name
- NCT05797233
- Testing
- Anti-CD19 and anti-CD20 bicistronic CAR T- cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B-cell Lymphoma
Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)
Newly diagnosed DLCL patients will have baselne FDG-PET as part of initial staging (PET-1). Patients will then undergo 2 cycles of chemotherapy with R/CHOP.
- Trial name
- NCT00754117
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Weill Medical College of Cornell University
Relapsed, Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)
This study is a phase 1, dose finding, open-label study in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT02658968
- Testing
- Betalutin
- Where
- 10 sites in United States, Germany and 3 more
- Volunteers
- 18 people
- Sponsor
- Nordic Nanovector
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
RATIONALE: Rasburicase may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying how well rasburicase works in preventing graft-versus-host…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00513474
- Testing
- busulfan, cyclophosphamide, cyclosporin-A
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Massachusetts General Hospital
B-Cell Lymphoma Stage I, Refractory
CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma
Evaluation the safety and efficacy of CD19/CD20 bispecific CAR-T cells in patients with relapsed/refractory B cell lymphoma
- Conditions
- B-Cell Lymphoma Stage I, Refractory, Relapsed
- Trial name
- NCT03881761
- Testing
- CD19/CD20 bispecific CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Henan Cancer Hospital
B-cell Lymphoma, Burkitt Lymphoma
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT).
- Conditions
- B-cell Lymphoma, Burkitt Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT04491370
- Testing
- Polatuzumab vedotin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- New York Medical College
Lymphoma, Non-Hodgkin
Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL
Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies.
- Trial name
- NCT04638270
- Testing
- anti-CD19 FasT CAR-T cells
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Xinqiao Hospital of Chongqing
Lymphoma
Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00070083
- Testing
- oblimersen sodium, rituximab, cyclophosphamide
- Where
- 4 sites in United States, Canada
- Sponsor
- British Columbia Cancer Agency
Healthy Volunteers, Arthritis, Rheumatoid
Characterization of Breg Cells
Recently, it has been shown that B cells could also have regulatory functions through the secretion of interleukin 10 (IL-10). They are called the B regulatory cells (Breg).
- Trial name
- Breg (NCT02615951)
- Testing
- blood sampling
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma
Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This study will evaluate the safety and effectiveness of a new drug called lenalidomide (Revlimid) for treating patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who relapsed after their…
- Trial name
- NCT00439231
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Georg Aue, M.D.
Vaccine-Preventable Diseases, Typhoid Fever
Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines
The goal of this clinical trial is to explore the coadministration of oral typhoid fever (Vivotif®) and cholera (Dukoral®) vaccines in healthy volunteers aged 18-65 years.
- Conditions
- Vaccine-Preventable Diseases, Typhoid Fever, Cholera
- Trial name
- NCT06104345
- Testing
- Oral typhoid fever vaccine, Oral cholera vaccine
- Where
- Finland
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Lymphoma, B-cell, Diffuse
Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma
For SyB L-0501RI administered by an intravenous rapid infusion in combination with rituximab, the safety will be investigated in previously untreated patients with low-grade B-cell non-Hodgkin's lymphoma (Lg-B-NHL) or mantle cell…
- Trial name
- NCT03900377
- Testing
- SyB L-0501RI
- Where
- 14 sites in Japan
- Volunteers
- 37 people
- Sponsor
- SymBio Pharmaceuticals
Mature B-cell Malignancies
Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies
The purpose of this study is to evaluate the safety and tolerability of BGB-11417 monotherapy, define the maximum tolerated dose (MTD) or maximum administered dose and the recommended Phase 2 dose (RP2D) of BGB-11417 monotherapy…
- Trial name
- NCT04883957
- Testing
- BGB-11417
- Where
- 11 sites in China
- Volunteers
- 64 people
- Sponsor
- BeiGene
Diffuse Large B Cell Lymphoma (DLBCL)
Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas.
This is a retrospective analysis of the presence of chromosomal rearrangements involving MYC, BCL2 and BCL6 genes by FISH in a retrospective, single-center series of large B-cell lymphomas, in order to allow a better…
- Trial name
- CHARTHER (NCT07181785)
- Testing
- Treatments: anthracycline-based combinations followed or not by involved-field radiotherapy
- Where
- Italy
- Volunteers
- 555 people
- Sponsor
- Andrés José Maria Ferreri
Lymphocytic Leukemia, Chronic
An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia
This observational study will monitor and register infusion-related adverse events and their handling in patients with chronic lymphocytic leukemia on treatment with MabThera (rituximab).
- Trial name
- NCT01072240
- Testing
- rituximab [Mabthera/Rituxan]
- Where
- 18 sites in Sweden
- Volunteers
- 92 people
- Sponsor
- Hoffmann-La Roche
B-cell Non Hodgkin Lymphoma
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL
The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC022F CAR-T cell immunotherapy in relapsed or refractory B-NHL.
- Trial name
- NCT04412174
- Testing
- GC022F
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hebei Yanda Ludaopei Hospital
Acute Lymphocytic Leukemia, Lymphoma
In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
The purpose of this study is to test the safety of giving the patient special cells from a donor called "Modified T-cells". The goal is to assess the toxicities of T-cells for patients with relapsed B cell leukemia or lymphoma…
- Trial name
- NCT01430390
- Testing
- Biological/Genetically Modified T cells, Cyclophosphamide-based chemotherapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.